OM:BONEXBiotechs
A Look At Bonesupport Holding (OM:BONEX) Valuation After Strong 2025 Growth And CERAMENT V FDA Progress
Bonesupport Holding (OM:BONEX) has just reported its 2025 year end results, highlighting 31% net sales growth, high margins and broader reach into US Level 1 trauma centers, alongside an FDA De Novo submission for CERAMENT V.
See our latest analysis for Bonesupport Holding.
The latest report comes after a mixed stretch for investors, with a 1 year total shareholder return decline of 48.83% contrasting with a very large 240.52% total shareholder return over 5 years. Recent 1 day and 7 day...